Literature DB >> 19323951

The dawn of prospective pharmacogenetic testing in type 2 diabetes.

Jose C Florez1.   

Abstract

Entities:  

Year:  2009        PMID： 19323951     DOI： 10.1007/s11892-009-0016-7

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN： 1534-4827            Impact factor:   4.810


× No keyword cloud information.
  10 in total

Review 1.  Clinical review: the genetics of type 2 diabetes: a realistic appraisal in 2008.

Authors:  Jose C Florez
Journal:  J Clin Endocrinol Metab       Date:  2008-09-09       Impact factor: 5.958

2.  Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.

Authors:  Ewan R Pearson; Isabelle Flechtner; Pål R Njølstad; Maciej T Malecki; Sarah E Flanagan; Brian Larkin; Frances M Ashcroft; Iwar Klimes; Ethel Codner; Violeta Iotova; Annabelle S Slingerland; Julian Shield; Jean-Jacques Robert; Jens J Holst; Penny M Clark; Sian Ellard; Oddmund Søvik; Michel Polak; Andrew T Hattersley
Journal:  N Engl J Med       Date:  2006-08-03       Impact factor: 91.245

3.  Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes.

Authors:  E R Pearson; W G Liddell; M Shepherd; R J Corrall; A T Hattersley
Journal:  Diabet Med       Date:  2000-07       Impact factor: 4.359

4.  The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes.

Authors:  Giorgio Sesti; Emanuela Laratta; Marina Cardellini; Francesco Andreozzi; Silvia Del Guerra; Concetta Irace; Agostino Gnasso; Maria Grupillo; Renato Lauro; Marta Letizia Hribal; Francesco Perticone; Piero Marchetti
Journal:  J Clin Endocrinol Metab       Date:  2006-04-04       Impact factor: 5.958

5.  Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region.

Authors:  Jose C Florez; Noël Burtt; Paul I W de Bakker; Peter Almgren; Tiinamaija Tuomi; Johan Holmkvist; Daniel Gaudet; Thomas J Hudson; Steve F Schaffner; Mark J Daly; Joel N Hirschhorn; Leif Groop; David Altshuler
Journal:  Diabetes       Date:  2004-05       Impact factor: 9.461

6.  The E23K variant of Kir6.2 associates with impaired post-OGTT serum insulin response and increased risk of type 2 diabetes.

Authors:  Eva-Maria D Nielsen; Lars Hansen; Bendix Carstensen; Søren M Echwald; Thomas Drivsholm; Charlotte Glümer; Birger Thorsteinsson; Knut Borch-Johnsen; Torben Hansen; Oluf Pedersen
Journal:  Diabetes       Date:  2003-02       Impact factor: 9.461

7.  Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes.

Authors:  Anna L Gloyn; Michael N Weedon; Katharine R Owen; Martina J Turner; Bridget A Knight; Graham Hitman; Mark Walker; Jonathan C Levy; Mike Sampson; Stephanie Halford; Mark I McCarthy; Andrew T Hattersley; Timothy M Frayling
Journal:  Diabetes       Date:  2003-02       Impact factor: 9.461

8.  Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study.

Authors:  Ewan R Pearson; Louise A Donnelly; Charlotte Kimber; Adrian Whitley; Alex S F Doney; Mark I McCarthy; Andrew T Hattersley; Andrew D Morris; Colin N A Palmer
Journal:  Diabetes       Date:  2007-05-22       Impact factor: 9.461

Review 9.  Genetic susceptibility to type 2 diabetes and implications for antidiabetic therapy.

Authors:  Allan F Moore; Jose C Florez
Journal:  Annu Rev Med       Date:  2008       Impact factor: 13.739

Review 10.  Genome-wide association studies provide new insights into type 2 diabetes aetiology.

Authors:  Timothy M Frayling
Journal:  Nat Rev Genet       Date:  2007-09       Impact factor: 53.242
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.